A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

NCT05525247 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

420

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: SLC-3010
COMBINATION_PRODUCT: Gemcitabine

Sponsor

Selecxine